Igyxos Biotherapeutics, a French biotechnology company, has secured a grant of EUR 5.7 million from the French Government to accelerate the development of its innovative monoclonal antibody for infertility treatment. The funding will support the Phase 2 clinical trials of the company’s lead asset, IGX12, in France and Europe. IGX12 is a first-in-class potentiating monoclonal antibody developed to enhance the potency and efficacy of follicle stimulating hormone (FSH), a critical hormone involved in female and male gametogenesis. Unlike current IVF treatment regimes, Igyxos’ approach addresses both female and male infertility. The company aims to bring a new therapeutic option to the millions of couples facing fertility challenges worldwide.